Evidence map›Paper›PMID 27608715›Full record

ArticleBreast cancer research : BCR2016

Plasma exosome microRNAs are indicative of breast cancer.

Bethany N Hannafon, Yvonne D Trigoso, Cameron L Calloway, Y Daniel Zhao, David H Lum, Alana L Welm, Zhizhuang J Zhao, Kenneth E Blick, William C Dooley, W Q Ding

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research : BCR, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 343 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
343citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

343 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review

283 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Bethany N HannafonDepartment of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.
Yvonne D TrigosoDepartment of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.
Cameron L CallowayDepartment of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.
Y Daniel ZhaoDepartment of Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.
David H LumOklahoma Medical Research Foundation, Oklahoma City, OK, 73104, USA.
Alana L WelmHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, 84112, USA.
Zhizhuang J ZhaoDepartment of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.
Kenneth E BlickDepartment of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.
William C DooleyDepartment of Surgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.
W Q DingDepartment of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA. weiqun-ding@ouhsc.edu.

Funding

Tracking and Evaluation CoreU54GM104938 · NIGMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI PAUL G SPICER · 2013 to 2026
$68.2M
VACCINE-TARGETED IDENTIFICATION OF FITNESS DETERMINANTS IN THE HIV-1 ENVELOPEP20RR016478 · NCRR · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI LEWIS, SHARON A · 2001 to 2011
$35.8M
NCRR NIH HHS P20 RR016478NIGMS NIH HHS U54 GM104938
6 · The paper itself

Abstract

backgroundmicroRNAs are promising candidate breast cancer biomarkers due to their cancer-specific expression profiles. However, efforts to develop circulating breast cancer biomarkers are challenged by the heterogeneity of microRNAs in the blood. To overcome this challenge, we aimed to develop a molecular profile of microRNAs specifically secreted from breast cancer cells. Our first step towards this direction relates to capturing and analyzing the contents of exosomes, which are small secretory vesicles that selectively encapsulate microRNAs indicative of their cell of origin. To our knowledge, circulating exosome microRNAs have not been well-evaluated as biomarkers for breast cancer diagnosis or monitoring.

methodsExosomes were collected from the conditioned media of human breast cancer cell lines, mouse plasma of patient-derived orthotopic xenograft models (PDX), and human plasma samples. Exosomes were verified by electron microscopy, nanoparticle tracking analysis, and western blot. Cellular and exosome microRNAs from breast cancer cell lines were profiled by next-generation small RNA sequencing. Plasma exosome microRNA expression was analyzed by qRT-PCR analysis.

resultsSmall RNA sequencing and qRT-PCR analysis showed that several microRNAs are selectively encapsulated or highly enriched in breast cancer exosomes. Importantly, the selectively enriched exosome microRNA, human miR-1246, was detected at significantly higher levels in exosomes isolated from PDX mouse plasma, indicating that tumor exosome microRNAs are released into the circulation and can serve as plasma biomarkers for breast cancer. This observation was extended to human plasma samples where miR-1246 and miR-21 were detected at significantly higher levels in the plasma exosomes of 16 patients with breast cancer as compared to the plasma exosomes of healthy control subjects. Receiver operating characteristic curve analysis indicated that the combination of plasma exosome miR-1246 and miR-21 is a better indicator of breast cancer than their individual levels.

conclusionsOur results demonstrate that certain microRNA species, such as miR-21 and miR-1246, are selectively enriched in human breast cancer exosomes and significantly elevated in the plasma of patients with breast cancer. These findings indicate a potential new strategy to selectively analyze plasma breast cancer microRNAs indicative of the presence of breast cancer.

Indexed as

Biomarkers, TumorAgedAged, 80 and overAnimalsBreast NeoplasmsCase-Control StudiesCell Line, TumorCulture Media, ConditionedDisease Models, AnimalExosomesFemaleGene Expression ProfilingHeterograftsHumansMiceMicroRNAsBiomarkers, TumorCulture Media, ConditionedMicroRNAsBiomarkerBreast cancerExosomesmicroRNAPatient-derived xenograft

Identifiers

PMID27608715
PMCPMC5016889

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.